A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVE

Trial Profile

A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVE

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Fallopian tube cancer; Malignant ascites; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms REZOLVE
  • Most Recent Events

    • 02 Apr 2015 Planned number of patients changed from 16 to 24 as per Australian New Zealand Clinical Trials Registry.
    • 02 Jul 2014 New trial record
    • 03 Jun 2014 Study protocol presented at the 50th Annual Meeting of the American Society of Clinical Oncology. 1 patient has been recruited and 3 of the 5 planned sites are open.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top